| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 12 Nov 2026 |
Form 4: Hamilton Thomas Edward, Director
Bought 70,000 shares ($187K) |
| 12 Nov 2026 |
Form 4: Ben-maimon Carole, Director
Bought 18,050 shares ($50K) |
| 12 Nov 2026 |
Form 4: Thomas Frank E, Director
Bought 8,000 shares ($21.8K) |
| 12 Nov 2026 |
Form 4: Truitt Joseph, Director
Bought 3,500 shares ($9.79K) |
| 12 Nov 2026 |
Form 4: Harlow John B. Jr., President and COO
Bought 17,800 shares ($49.9K) |
| 12 Nov 2026 |
Form 4: Celano Michael, Chief Financial Officer
Bought 18,460 shares ($50K) |
| 12 Nov 2026 |
Form 4: Shankar Gopi, Chief Development Officer
Bought 5,000 shares ($13.5K) |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
pro November 2026 Larimar Therapeutics Corporate Deck Exhibit 99.2 |
| 01 Oct 2026 |
Form 4: Harlow John B. Jr., President and COO
Received 50,000 shares as a grant or award · Granted 800,000 Stock Option (Right to Buy) |
| 01 Oct 2026 |
Form 3: Harlow John B. Jr., President and COO
No securities owned |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the... |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update |
| 08 Jul 2026 |
Form 4: Hamilton Thomas Edward, Director
Bought 50,000 shares ($167K) |
| 29 Jun 2026 |
8-K: Other Events
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia |
| 20 May 2026 |
Form 4: Flynn James E, Director and 1 other
Granted 55,150 Stock Option (Right to Buy) |
| 20 May 2026 |
Form 4: Leff Jonathan S, Director
Granted 55,150 Stock Option (Right to Buy) |
Loading...